Clinical Trials for Impact Therapeutics

Explore 5 clinical trials worldwide

Showing 1-5 of 5 trials

Active filters:Status: Recruiting, Active, not recruiting, Enrolling by invitation, Not yet recruitingSponsor: Impact Therapeutics

Clinical Trials (5)

NCT06907043
A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.
PHASE1/PHASE2Recruiting
130 participants
Started: Apr 30, 2025 · Completed: Dec 31, 2028
1 condition2 sponsors10 locations
NCT06617923
Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer
PHASE2Recruiting
18 participants
Started: Feb 6, 2025 · Completed: Dec 31, 2029
3 conditions3 sponsors1 location
NCT06253130
A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors
PHASE1/PHASE2Recruiting
70 participants
Started: Dec 11, 2023 · Completed: Dec 1, 2026
1 condition2 sponsors24 locations
NCT05269316
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
PHASE1/PHASE2Recruiting
61 participants
Started: Feb 11, 2022 · Completed: Dec 31, 2026
2 conditions1 sponsor8 locations
NCT04169997
A Study of IMP4297 as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer
PHASE3Active, not recruiting
404 participants
Started: Dec 24, 2019 · Completed: Jun 30, 2026
1 condition1 sponsor2 locations